乳腺癌诊断时生育力保存操作后的复发率与疾病特异性死亡率
这项瑞典全国前瞻性队列研究纳入1275例乳腺癌诊断时女性,比较接受激素刺激或非激素生育力保存者与未接受者的预后。调整混杂后,激素生育力保存者疾病特异性死亡aHR 0.59(95%CI 0.32-1.09),非激素生育力保存者aHR 0.51(95%CI 0.20-1.29),与未暴露者相似;亚组中复发与死亡风险亦相似。结论认为生育力保存与复发或疾病特异性死亡风险增加无关。
要点
- 乳腺癌诊断时接受激素或非激素生育力保存,疾病特异性死亡风险与未接受者相似。
- 激素生育力保存者疾病特异性死亡aHR 0.59(95%CI 0.32-1.09),未达统计学显著。
- 亚组中激素生育力保存者疾病特异性死亡与复发aHR 0.81(95%CI 0.49-1.37)。
核心结论
- 乳腺癌诊断时接受含或不含激素刺激的生育力保存,与复发或疾病特异性死亡风险增加无关。
- 作者认为该结果为乳腺癌女性生育力保存操作的安全性提供了急需的额外证据,可能影响现行医疗实践,使希望保留生育力的年轻乳腺癌女性获益。
研究设计与样本
- 瑞典全国前瞻性队列研究,评估1994年1月1日至2017年6月30日期间乳腺癌指征下激素与非激素生育力保存操作的安全性。
- 女性从瑞典大学医院区域生育力保存项目中识别,共425例接受生育力保存,从区域乳腺癌登记中按年龄、诊断日历年及地区匹配抽取850例未接受生育力保存的人群对照。
- 无复发生存分析在241例接受生育力保存与482例未接受且数据完整的女性亚组中进行。
- 全国人口与医疗登记提供结局、疾病与治疗相关变量及社会经济特征数据;数据分析于2021年11月至2022年3月进行,2022年6月完成。
主要发现
- 最终研究人群共1275例女性,乳腺癌诊断时平均(SD)年龄32.9(3.8)岁。
- 按匹配变量年龄、日历年及地区分层并调整出生国、教育、诊断时产次、肿瘤大小、淋巴结转移数目及雌激素受体状态后,激素生育力保存者疾病特异性死亡aHR 0.59(95%CI 0.32-1.09),非激素生育力保存者aHR 0.51(95%CI 0.20-1.29),未暴露于生育力保存者为参照。
- 在具有详细复发数据的亚组中,激素生育力保存者疾病特异性死亡与复发aHR 0.81(95%CI 0.49-1.37),非激素生育力保存者aHR 0.75(95%CI 0.35-1.62),未暴露于生育力保存者为参照。
临床怎么用
- 原文结论认为生育力保存操作与复发或疾病特异性死亡风险增加无关,可能影响现行医疗实践,使希望保留生育力的年轻乳腺癌女性获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Breast cancer (BC) is the most common indication for fertility preservation (FP) in women of reproductive age. Procedures for FP often include hormonal stimulation, but current data are scarce regarding whether using hormonal stimulation for FP is associated with any deterioration in BC prognosis. OBJECTIVE: To investigate the risk of disease-specific mortality and relapse in women who underwent FP with or without hormonal stimulation compared with women who did not at time of BC diagnosis. DESIGN, SETTING, AND PARTICIPANTS: This Swedish nationwide prospective cohort study was conducted to assess the safety of hormonal and nonhormonal FP procedures indicated by BC in Sweden from January 1, 1994, through June 30, 2017. Women were identified from any of the regional FP programs located at Swedish university hospitals. A total of 425 women were found to have undergone FP, and 850 population comparators who had not undergone FP were sampled from regional BC registers and matched on age, calendar period of diagnosis, and region. Relapse-free survival was assessed in a subcohort of 241 women who underwent FP and 482 women who had not, with complete data. Nationwide demographic and health care registers provided data on outcome, disease- and treatment-related variables, and socioeconomic characteristics. Data analyses were performed between November 2021 and March 2022 and completed in June 2022. MAIN OUTCOMES AND MEASURES: Relapse and disease-specific mortality after a diagnosis of BC. RESULTS: The final study population included 1275 women (mean [SD] age, 32.9 [3.8] years) at the time of BC diagnosis. After stratification by the matching variables age, calendar period, and region, and adjustment for country of birth, education, parity at diagnosis, tumor size, number of lymph node metastases, and estrogen receptor status, disease-specific mortality was similar in women who underwent hormonal FP (adjusted hazard ratio [aHR], 0.59; 95% CI, 0.32-1.09), women who underwent nonhormonal FP (aHR, 0.51; 95% CI, 0.20-1.29), and women who were not exposed to FP (reference). In a subcohort with detailed data on relapse, adjusted rate of disease-specific mortality and relapse were also similar among the groups who underwent hormonal FP (aHR, 0.81; 95% CI, 0.49-1.37), underwent nonhormonal FP (aHR, 0.75; 95% CI, 0.35-1.62), and were not exposed to FP (reference). CONCLUSIONS AND RELEVANCE: In this cohort study, FP with or without hormonal stimulation was not associated with any increased risk of relapse or disease-specific mortality in women with BC. Results of this study provide much needed additional evidence on the safety of FP procedures in women with BC and may influence current health care practice to the benefit of young women with BC who wish to preserve their fertility.
引用
- Marklund A, Lekberg T, Hedayati E, et al. Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis. JAMA Oncol. 2022. PMID: 36006625. doi:10.1001/jamaoncol.2022.3677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。